Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee

Osteoarthritis (OA) currently affects over 40 million Europeans, with its associated personal suffering and significant economic burden for health systems set to dramatically escalate in a rapidly ageing Europe. Given the very limited effective therapeutic options for OA, the European League Against Rheumatism (EULAR) created an ad hoc committee of OA researchers, clinicians and patients to consider a research agenda focussed on the areas of epidemiology, pathogenesis, imaging and biomarkers, and therapies. The committee deliberated and listed research needs in these areas and also established some cross-area priority themes: predictors of OA progression, especially where this might enable stratified interventions; understanding mechanisms of OA pain; improved understanding of tissue communication in a process where multiple tissue pathologies are common; developing concepts of, and consequently interventions for, early OA where both pain and structural processes may be more effectively targeted than in typical clinical presentations; and the need for new treatment strategies, with examples discussed on pathology-targeted therapies and optimal combinations of therapies. This research agenda should provide useful guidance for all researchers in this field and hopefully lead to improved OA care.

[1]  C. Cooper,et al.  Value of biomarkers in osteoarthritis: current status and perspectives , 2013, Annals of the rheumatic diseases.

[2]  W. B. van den Berg,et al.  Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration? , 2012, Osteoarthritis and cartilage.

[3]  Philip G Conaghan,et al.  Imaging the painful osteoarthritic knee joint: what have we learned? , 2009, Nature Clinical Practice Rheumatology.

[4]  J. Jordan,et al.  "Generalized osteoarthritis": a systematic review. , 2014, Seminars in arthritis and rheumatism.

[5]  C. H. Coyle,et al.  Early diagnosis to enable early treatment of pre-osteoarthritis , 2012, Arthritis Research & Therapy.

[6]  F. Berenbaum,et al.  Osteoarthritis: an update with relevance for clinical practice , 2011, The Lancet.

[7]  J. Kroin,et al.  A current review of molecular mechanisms regarding osteoarthritis and pain. , 2013, Gene.

[8]  M. Viergever,et al.  CHECK (Cohort Hip and Cohort Knee): similarities and differences with the Osteoarthritis Initiative , 2008, Annals of the rheumatic diseases.

[9]  L. Danielsson,et al.  Prevalence of Coxarthrosis in an Urban Population During Four Decades , 1997, Clinical orthopaedics and related research.

[10]  Bernadette A. Thomas,et al.  Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[11]  E. Lévy,et al.  [Socioeconomic costs of osteoarthritis in France]. , 1993, Revue du rhumatisme.

[12]  Ali Guermazi,et al.  Osteoarthritis: a review of strengths and weaknesses of different imaging options. , 2013, Rheumatic diseases clinics of North America.

[13]  J. Reginster,et al.  Direct and indirect costs attributable to osteoarthritis in active subjects. , 2006, The Journal of rheumatology.

[14]  Bernadette A. Thomas,et al.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[15]  R. Geenen,et al.  EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis , 2013, Annals of the rheumatic diseases.

[16]  F. Berenbaum,et al.  Is osteoarthritis a metabolic disease? , 2013, Joint, bone, spine : revue du rhumatisme.

[17]  F. Salaffi,et al.  Direct and indirect costs of osteoarthritis of the knee. , 2004, Clinical and experimental rheumatology.

[18]  C. Christiansen,et al.  The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? , 2013, Annals of the rheumatic diseases.

[19]  E. Batlle-Gualda,et al.  Economic burden of knee and hip osteoarthritis in Spain. , 2009, Arthritis and rheumatism.

[20]  C. Le Pen,et al.  Financial cost of osteoarthritis in France. The "COART" France study. , 2005, Joint, bone, spine : revue du rhumatisme.

[21]  A. Cats,et al.  Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. , 1989, Annals of the rheumatic diseases.

[22]  Joost Dekker,et al.  Biomechanical factors and physical examination findings in osteoarthritis of the knee: associations with tissue abnormalities assessed by conventional radiography and high-resolution 3.0 Tesla magnetic resonance imaging , 2012, Arthritis Research & Therapy.

[23]  M. Davidsen,et al.  The Danish National Cohort Study (DANCOS) , 2003, Scandinavian journal of public health.

[24]  H. Menz,et al.  The population prevalence of symptomatic radiographic foot osteoarthritis in community-dwelling older adults: cross-sectional findings from the Clinical Assessment Study of the Foot , 2013, Annals of the rheumatic diseases.

[25]  G. Baxter,et al.  Patient characteristics that predict progression of knee osteoarthritis: A systematic review of prognostic studies , 2011, Arthritis care & research.

[26]  P. Vavken,et al.  Burden of musculoskeletal disease and its determination by urbanicity, socioeconomic status, age, and sex: Results from 14,507 subjects , 2011, Arthritis care & research.

[27]  L. Abasolo,et al.  Burden of disease across chronic diseases: a health survey that measured prevalence, function, and quality of life. , 2008, The Journal of rheumatology.

[28]  B. Collett,et al.  Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment , 2006, European journal of pain.